




5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS



Virtual Meet

22nd - 24th
JULY 2022

ORGANISING
TEAM



Dr. Anil Heroor
Director Surgical Oncology,
Fortis Hospital,
Mumbai



Dr. Tejinder Singh
Sr. Consultant Medical Oncologist
Apollo Cancer Center,
Apollo Hospital, Mumbai



Dr. Adwaita Gore
Associate Director Medical Oncology
Nanavati Max Super Speciality,
Mumbai

Click on below link to register
<https://www.riverroute.in/gireview>

Managed by **riverroute**
Leaders in Streaming Modules



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Dear Colleagues,

GKCT brings to you the 5th Edition of Annual Review in Gastrointestinal Cancer to be held on 22nd-24th July 2022 on a Virtual Platform.

The primary goal of this meeting is to guide practicing physicians on integrating the best and most current evidence into day-to-day routine care for patients with GI cancers. This meeting brings a practical perspective on how to optimize multidisciplinary care for some of the more complex clinical management decisions. Topics discussed include locoregional modalities, the role of minimally invasive procedures, and state-of-the-art treatment.

As we are aware chemotherapy dependency has maintains its validity in several gastrointestinal cancers and continues to be successfully explored, especially in academic trials. However, a number of biomarkers currently guide treatment decisions for patients with gastrointestinal neoplasms. Major technological advances in genomics have made it possible to identify critical genetic alterations in cancer, rendering oncology well along the path to “personalized cancer medicine”.

Image-guided surgery & minimally invasive treatment has evolved over the past several decades, which has led to reduced local recurrence rates and improved survival outcomes. The approach to diagnosis, staging, and selection of appropriate treatment modalities has become a multidisciplinary effort combining interventional endoscopy, surgery, and radiology tools needs to be discussed and implemented in our practice.

This meeting focuses on case-based and didactic presentations from national international experts in the treatment of the whole spectrum of gastrointestinal (GI) cancers, including esophageal, gastric, hepatocellular, pancreatic, small bowel, bile duct, anal and colorectal, and gallbladder. Our year in review session, hall mark surgical video sessions and case based panel discussion will provide an overview of exciting new research in the area of gastrointestinal tumours that may establish the stage for an innovative personalized management and precision medicine modalities for individualized care.

We are sure our attempt in understanding the various therapeutic interventions will pave the way for improved patient outcomes. We look forward to your active participation.

Regards

Dr. Anil Heroor

Director Surgical Oncology,
Fortis Hospital,
Mumbai

Dr. Tejinder Singh

Sr. Consultant Medical Oncologist
Apollo Cancer Center,
Apollo Hospital, Mumbai

Dr. Adwaita Gore

Associate Director Medical Oncology
Nanavati Max Super Speciality,
Mumbai

Click on below link to register
<https://www.riverroute.in/gireview>

Managed by **riverroute**
Leaders in Streaming Modules



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

MEETING HIGHLIGHTS

- Surgical Master Video Session
- Year in Review in GI Cancer Session
- Molecular Tumor Board and Case Based Panel Discussion
- Eminent Speaker Sessions (Surgical and Medical)
- Molecular Oncology Session



Click on below link to register
<https://www.riverroute.in/gireview>

Managed by **riverroute**
Leaders in Streaming Modules



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Day 1 | 22nd July 2022 Scientific Program

Industry Symposium

6.00pm – 6.30pm

Sponsored by Bristol Myers Squibb
Immune checkpoint inhibitors in 1L
Gastric Cancer, GEJC and EAC

Speaker: Dr. Tejinder Singh

6.30pm – 7.00pm

Sponsored by Intas
Role of S1 in GI management in
Indian Scenario

Speaker: Dr. Prabhat Bhargava

7.00pm – 7.30pm

Sponsored by AstraZeneca
Newer Avenues in Management of
Advanced BTC

Speaker: Dr. B.K. Smruti

7.30pm – 8.00pm

Recent Advances in the
Management of Second Line
Gastric Cancer

Speaker: Dr. Ashish Singh

8.00pm – 8.30pm

Sponsored by Roche
Panel Discussion on Treatment
Strategies with Atezolizumab &
Bevacizumab in Unresectable HCC

Moderator - Dr. Bhushan Nemade

Panelists –
Dr. Tejinder Singh
Dr. Preetam Jain
Dr. Aditya Kale
Dr Amit Mandot
Dr. Rahul Sheth



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Day 2 | 23rd July 2022 Scientific Program

Session 1 : Esophagus/Stomach Cancers

6:00pm – 6:10pm	<p>Chairpersons - Dr. Shirish Alurkar Dr. Girish Phadke</p> <p>Updates in Surgical Management of Localized EG Cancers Speaker: Dr. M. Satish Kumar</p>
6:10pm – 6:20pm	<p>Management of Metastatic EG Cancer Speaker: Dr. Pritam Kalaskar</p>
6:20pm – 6:40pm	<p>Should all Patients with EG Cancer Receive Immunotherapy? Yes – Dr. M. Vamshi Krishna No – Dr. Peush Bajpai Debate Moderator : Dr. Bharat Bhosale</p>
6:40pm – 7:10pm	<p>Chairpersons - Dr. Satish Midha Dr. Atul Sharma</p> <p>Panel Discussion: Practice Changing Papers in Esophageal / Gastric Cancers Moderator: Dr. Vedant Kabra</p> <p>Panelists: Dr. Rajesh Shinde Dr. Rudraprasad Acharya Dr. Gajanan Kanitkar Dr. Atul Narayankar Dr. Sandeep De Dr. Indranil Mallick Dr. Nikhil Kalyani Dr. Nilesh Lokeshwar Dr. Nikhil Gulavani Dr. Mukurdipi Ray</p>

Click on below link to register
<https://www.riverroute.in/gireview>

Managed by **riverroute**
Leaders in Streaming Modules



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Day 2 | 23rd July 2022 **Scientific Program**

Session 2 : Pancreatic Cancer

7:10pm – 7:35pm

Chairpersons -
Dr. D. C. Doval
Dr. Abhijit Talukdar

**Debate : Borderline Resectable
Pancreatic Cancer**

To Radiate : Dr. Manish Chandra

Not To Radiate: Dr. Shaikat Gupta

Debate Moderator:
Dr. Adarsh Chaudhary

7:35 – 7:50pm

**Advances in the Systemic Treatment
of Pancreatic Cancer**

Speaker: Dr. Niti Raizada

7:50pm – 8:20pm

Chairpersons -
Dr. Sanjay Sonar
Dr. Shefali Agrawal

**Panel Discussion: Practice Changing
Papers in Pancreatic Cancers**

Moderator: Dr. Chetan Kantharia

Panelists:
Dr. Rajat Bhargava
Dr. Caleb Harris
Dr. Ramakrishnan A.S.
Dr. Deepanjali Adulkar
Dr. Upasna Saxena
Dr. Amol Dongre
Dr. Krishnakumar Rathnam
Dr. Sujai Hegde



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Day 2 | 23rd July 2022 Scientific Program

Session 3 : Hepatocellular Carcinoma / Ca Gall Bladder

8:20pm – 8:45pm

Chairpersons -
Dr. S. H. Advani
Dr. Naresh Somani

**Debate : Integrating Immunotherapy
Into Earlier-Stage HCC**

Yes – Dr. Pritam Kataria

Not Yet – Dr. Ravi Jaiswal

Debate Moderator:
Adwaita Gore

8:45pm – 9:00pm

**Leaping the Boundaries of Liver
Cancer Surgery**

Speaker: Dr. Ganesh Nagrajan

9:00pm – 9:30pm

Chairpersons -
Dr. Vivek Agarwala
Dr. Shishir Shetty

**Panel Discussion: Practice Changing
Papers in HCC/Gall Bladder**

Moderator: Dr. Vineet Talwar

Panelists:
Dr. Shraddha Patkar
Dr. Aniruddha Kulkarni
Dr. Nikhil Pande
Dr. Chandrakanth M.V.
Dr. Suhas Aagre
Dr. Sandeep Bhorawal
Dr. Shailesh Bondarde
Dr. Chandrashekhar Pethe



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Day 3 | 24th July 2022 **Scientific Program**

Session 4 : Colorectal Cancers

6:00pm – 6:10pm

Chairpersons -
Dr. K Pavithran
Dr. Mehul Bhansali

Tailoring Treatment for Early-Stage CRC

Speaker: Dr. Avanish Saklani

6:10pm – 6:35pm

Debate: What's the Best Sequence of Therapy for Locally Advanced Rectal?

Radiation First :
Dr. Reena Engineer
Chemotherapy First :
Dr. Chetan Deshmukh

6:35pm – 6:45pm

Finding the Optimal Window for Anti-EGFR Treatment

Speaker: Dr. Prasad Narayanan

6:45pm – 6:55pm

New and Emerging Later-Line Therapies in Advanced CRC

Speaker: Dr. Rahul Kulkarni

6:55pm – 7:20pm

Chairpersons -
Dr. Rajeev Joshi
Dr. Avinash Supe

Debate: Quadruple or Triple Therapy in First-Line Advanced CRC

Quadruple Therapy :
Dr. Bhuvan Chugh
Triplet Therapy
Dr. Prabhat Bhargava

Moderator: Dr. Manish Kumar



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Day 3 | 24th July 2022 Scientific Program

Session 4 : Colorectal Cancers

7:20pm – 7:50pm

Panel discussion: Practice Changing Abstracts in CRC

Moderator: Dr. Nitesh Rohatgi

Panelists:

Dr. Wesley Jose

Dr. Nirmal Raut

Dr. Smita Kayal

Dr. Ashwin Desouza

Dr. Deep Goel

Dr. Sandeep Nayak

Dr. Poornima Subrahmanya

7:50pm – 8:50pm

Chairpersons -

Dr. Anuradha Chougule

Dr. P. K. Julka

Molecular Tumour Board

Moderator: Dr. T. Raja

Panelists:

Dr. Amit Rauthan

Dr. B. K. Smruti

Dr. Suparna Rao

Dr. Tejinder Singh

Dr. Uma Dangi

Dr. Bharat Bhosale

8:50pm – 9:00pm

Vote of Thanks

Conference managed by:

riverroute®

▣ Leaders in Streaming Modules

Amey Kadam

Conference Secretariat

rrcg.amey@gmail.com | Mobile +91 98212 41572

Click on below link to register
<https://www.riverroute.in/gireview>

Managed by **riverroute®**
▣ Leaders in Streaming Modules



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

Supported By

Diamond Sponsor



Platinum Sponsors



Gold Sponsors



Silver Sponsors





5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022



S-One Trio 15 mg
20 mg

Tegafur + Gimeracil + Oteracil Potassium



for

Advanced Gastric Cancer together with Cisplatin



Tegafur

Prodrug of
5-fluorouracil (5-FU)
Replacement for infusional 5-
FU therapy

**Increased
Convenience**

Oteracil

Modulator to reduce
unwanted
5-FU-induced
gastrointestinal toxicity,
as it is related to
phosphorylation of 5-FU

**Reduced
Toxicity**

Gimeracil

Modulator to enhance the
efficacy of tegafur by
inhibiting catabolism and
subsequent inactivation of 5-
FU by inhibiting the enzyme
DPD, so that concentrations
of 5-FU are maintained for a
longer period of time

**Enhanced
Efficacy**



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022


CYRAMZA[™]
(ramucirumab)

**FORTITUDE
WITH 5 YEARS*
INDICATIONS**



2nd Line advanced Gastric
Cancer / GE Junction
adenocarcinoma



2nd Line metastatic
Colorectal Cancer



1st Line EGFRm+
metastatic Non Small
Cell Lung Cancer



2nd Line advanced
or unresectable
Hepatocellular Carcinoma



2nd Line locally
advanced or metastatic
Non Small Cell Lung Cancer

22nd - 24th JULY 2022



Marketed in India by :
Roche Products (India) Pvt. Ltd.
 146-B, 166A, Unit No. 7,8,9, 8th Floor,
 R City Office, R City Mall, Lal Bahadur Shastri Marg,
 Ghatkopar, Mumbai - 400 086, India
 Tel.: +91 (22) 5045 7300 • Fax: +91 (22) 5045 7301



netupitant/palonosetron

PREVENTION MADE SIMPLE

Legal category: Medical Prescription Product, Marketing authorization number EU/19/001/001, Marketing authorization holder Hektin Bire Pharmaceuticals LLC, Darmstadt, Main Street, D68315, Isenhardt, Reporting suspected adverse reactions after authorisation of medicinal products in Europe. It is important to continue monitoring of the beneficial balance of Aynozon®. Healthcare professionals are asked to report any suspected adverse reactions according to their national provisions. Adverse reactions should be reported to Hektin Bire Pharmaceuticals LLC (address as above) Tel: +33 (0) 8 858532. Aynozon® is marketed exclusively by Hektin Bire Pharmaceuticals.

ADN Ref.: Aynozon® 2020 Jan 2020

For further product related queries contact: German Pharmaceuticals Limited (GFL), Corporate Office, B-12, Swarnit Marg, Chokhi, Andheri (E), Mumbai - 400 059, Email id: gfl@germanpharmaceuticals.com,
For more information about Aynozon® please visit our website at www.aynozon.com or www.germanpharmaceuticals.com.

40177790/1.VM



5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022



For the management of advanced HCC

^{Rx} **Lenvenib**[®]
Lenvatinib 4mg/10mg Capsules
a **NEW** standard

^{Rx} **Cabozat**[™]
Cabozantinib 20/40 mg Tablets
*Improve **Survival** with a **Masterstroke***

- Developed **in house** right from basic API to finished product*
- **Bioequivalent** to the innovator
- Manufactured in **USFDA** approved plant for benchmark quality*



* Data on file.





5TH ANNUAL INTERNATIONAL REVIEW ON GI CANCERS

22nd - 24th JULY 2022

With Best Compliments from



Makers of

Fulzos
FULVESTRANT 250 mg PFS

RE-SETLife



CIZUMABTM
BEVACIZUMAB 100 mg / 400 mg [n]

Impeding **Angiogenesis**



A / B - 201 / 202, Dipti Classic, 32 / 34, W.T. Suren Road, Andheri (East), Mumbai - 400 093, India
Tel: +91 22 2684 93 38 / 39 / 40 Fax: +91 22 2684 9355 E-mail: ho@heterohealthcare.com